Fate Therapeutics (FATE) Other Accumulated Expenses (2013 - 2026)

Fate Therapeutics has reported Other Accumulated Expenses for 14 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 41.48% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 41.48% YoY), and the FY2025 full-year result was $4.4 million, down 30.62% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $4.0 million, down from $4.4 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $19.2 million in Q4 2022, with the low at $3.9 million in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $9.8 million across 5 years, with a median of $8.1 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 126.86% — and 2025, when it plunged 63.72%.
• Fate Therapeutics' Other Accumulated Expenses stood at $19.2 million in 2022, then plunged by 57.66% to $8.1 million in 2023, then declined by 21.67% to $6.4 million in 2024, then sank by 30.62% to $4.4 million in 2025, then dropped by 10.24% to $4.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.0 million (Q1 2026), $4.4 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.